Logo Image
|Podcasts|February 24, 2023

Episode 83: The ARISE Study and Using DMTs in RIS

Author(s)Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Darin Okuda, MD. [LISTEN TIME: 21 minutes]

Episode 83 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 83, "The ARISE Study and Using DMTs in RIS," features an exclusive interview with Darin Okuda, MD, FAAN, FANA, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center. He spoke about the phase 2 ARISE study assessing dimethyl fumarate (Tecfidera; Biogen) in patients with radiologically isolated syndrome, the significance of the findings, next steps in validating this therapy, and more.

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

EPISODE BREAKDOWN

  • 1:20 – Overview of ARISE and conduct of study
  • 4:20 – Potential subgroup responders to dimethyl fumarate
  • 8:10 – Efforts to improve the detection of radiologically isolated syndrome
  • 10:05 – Neurology News Minute
  • 11:55 – Next steps of research following ARISE
  • 16:50 – Closing thoughts on significance of the study

Click here to subscribe to the Mind Moments® podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

REFERENCE
Okuda DT, Kantarci O, Lebrun-Frenay C, et al. Dimethyl fumarate delays multiple sclerosis radiologically isolated syndrome. Ann Neurol. 2023;93(3):604-614. doi:10.1002/ana.26555

Related to this article

View more
New York Forum Tackles Unmet Needs in Multiple Sclerosis Care
New York Forum Tackles Unmet Needs in Multiple Sclerosis Care
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
Read more
Awareness, Not Access, Remains the Barrier to NF1 Therapy
Awareness, Not Access, Remains the Barrier to NF1 Therapy
At a NeurologyLive Clinical Forum in Phoenix, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how NF1-associated plexiform neurofibromas get recognized, referred, and treated.
Read more